Sauerbrun-Cutler May-Tal, Rollo Allegra, Gadson Alexis, Eaton Jennifer L
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Women and Infants Hospital and Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
J Clin Med. 2024 Feb 14;13(4):1072. doi: 10.3390/jcm13041072.
Fertility preservation (FP) is the use of a specific medical intervention to protect the fertility of individuals whose disease or disease treatment may lead to infertility. These medical interventions include the cryopreservation of oocytes, embryos, ovarian tissue, sperm, and testicular tissue; oocyte and embryo cryopreservation are the most widely used interventions in the United States. Although guidelines recommend FP prior to undergoing gonadotoxic treatments, cost barriers are high. For example, the average cost of an oocyte cryopreservation cycle in the United States exceeds $10,000. High cost and lack of insurance coverage are two of the most cited reasons explaining the low Reproductive Endocrinology and Infertility (REI) referral rates and limited FP utilization. Broadening insurance mandates for FP prior to gonadotoxic treatments could improve utilization and provide cancer survivors with improved quality of life post treatment.
生育力保存（FP）是指使用特定的医学干预措施来保护那些因疾病或疾病治疗可能导致不孕的个体的生育能力。这些医学干预措施包括卵母细胞、胚胎、卵巢组织、精子和睾丸组织的冷冻保存；在美国，卵母细胞和胚胎冷冻保存是使用最广泛的干预措施。尽管指南建议在接受性腺毒性治疗之前进行生育力保存，但成本障碍很高。例如，在美国，一个卵母细胞冷冻保存周期的平均成本超过10000美元。高成本和缺乏保险覆盖是导致生殖内分泌与不孕（REI）转诊率低和生育力保存利用率有限的两个最常被提及的原因。扩大在性腺毒性治疗之前对生育力保存的保险授权可以提高利用率，并为癌症幸存者提供治疗后更高的生活质量。
